Journal of Leukocyte Biology BioLegend: Treg, Th17, Stem Cell
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published online as doi:10.1189/jlb.1105652 on July 24, 2006

Published online before print July 24, 2006
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jlb.1105652v1
80/4/719    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pfaff, D.
Right arrow Articles by Augustin, H. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pfaff, D.
Right arrow Articles by Augustin, H. G.
(Journal of Leukocyte Biology. 2006;80:719-726.)
© 2006 by Society for Leukocyte Biology

Emerging roles of the Angiopoietin-Tie and the ephrin-Eph systems as regulators of cell trafficking

Dennis Pfaff*, Ulrike Fiedler{dagger} and Hellmut G. Augustin*,{dagger},1

* Department of Vascular Oncology and Metastasis, Joint Research Division Vascular Biology of the University of Heidelberg (Mannheim Campus) and the German Cancer Research Center Heidelberg (DKFZ), Heidelberg, Germany; and
{dagger} Department of Vascular Biology and Angiogenesis Research, Tumor Biology Center Freiburg, Germany

1 Correspondence: Department of Vascular Oncology and Metastasis, German Cancer Research Center, INF581, D-69120 Heidelberg, Germany. E-mail: augustin{at}angiogenese.de

ABSTRACT

Vascular receptor tyrosine kinases (RTK) have been identified as critical regulatory signaling molecules of developmental and adult vascular morphogenic processes [vascular endothelial growth factor (VEGF) receptors=sprouting; EphB receptors=assembly; Tie2 receptor=maturation and quiescence]. It is intriguing that the same molecules that control the growth of blood and lymphatic vessels play critical roles in the adult to regulate maintenance functions related to vascular homeostasis. VEGF is among the most potent inducers of vascular permeability. The second vascular RTK system, the interaction of paracrine-acting Angiopoietin-1 with its cognate receptor Tie2, acts as an endothelial maintenance and survival-mediating molecular system, which stabilizes the vessel wall and controls endothelial cell quiescence. The third vascular RTK system, the interaction of Eph receptors with their Eph family receptor-interacting protein (ephrin) ligands, transduces positional guidance cues on outgrowing vascular sprouts, which are critical for proper arteriovenous assembly and establishment of blood flow. As such, Eph-ephrin interactions act as an important regulator of cell–cell interactions, exerting propulsive and repulsive functions on neighboring cells and mediating adhesive functions. This review summarizes recent findings related to the roles of the Angiopoietin-Tie and the Eph-ephrin systems as regulators of cell trafficking in the vascular system. The recognition of vascular homeostatic functions of vascular RTKs marks an important change of paradigm in the field of angiogenesis research as it relates angiogenesis-inducing molecules to vascular maintenance functions in the adult. This may also broaden the scope of vascular RTK-targeted therapies.

Key Words: adhesion • angiogenesis • receptor tyrosine kinases • endothelium

INTRODUCTION

The vascular endothelium controls the passage of plasma and cells from the vascular to the extravascular space. As such, endothelial cells form a nonthrombogenic surface, which acts as permeability and extravasation barrier [1 ]. Gowans [2 ] and Palade and co-workers [3 ] were first to independently report that leukocytes interact with the endothelium in postcapillary venules. These key observations suggested that the endothelial layer can undergo a transition from the quiescent, antiadhesive state to an activated, adhesive state [4 ]. Further studies showed that activation of the endothelium is controlled by multiple factors and processes. These include physical damage, hypoxia, increased shear stress, as well as bacterial and viral infections. Collectively, these physical, chemical, and biological stimuli result in an inflammatory response, which is triggered by soluble factors such as thrombin, histamine, endotoxin, oxidized lipoproteins, prostaglandins, leukotrienes, IL-1, IL-6, IL-8, TNF-{alpha}, and vascular endothelial growth factor (VEGF). As a consequence, the endothelium becomes activated, which leads to the recruitment of inflammatory cells, thrombus formation, and local fluid accumulation, which is associated with locally reduced blood flow and increased permeability [1 , 4 ].

The molecular mechanisms regulating the fast transition of the quiescent to the activated endothelium in response to tissue damage have only been partly uncovered. Activation of endothelial cells triggers immediate responses as well as a slower transcriptionally regulated response program. Immediate responses involve presynthesized molecules, which are stored within endothelial cells themselves. The cell-specific storage granules of endothelial cells are named after their discoverers Weibel-Palade bodies (WPB) [5 ]. The main constituent of WPB is the von Willebrand-factor (vWF). WPB store, in addition to the processed multimeric form of vWF, P-selectin, CD63, IL-8, endothelin-1, and its converting enzyme, tissue-type plaminogen activator (t-PA), and Angiopoietin-2 (Ang-2) [5 ]. All of these molecules are involved in the regulation of fast endothelial responses including hemostasis (vWF), inflammation (P-selectin, IL-8, Ang-2), hemodynamic adaptation (endothelin-1), fibrinolysis (t-PA), and permeability (Ang-2). WPB are released in response to multiple secretagogues (thrombin, histamine, peptide-leukotrienes, complement components C5a and C5b-9, superoxide anion, VEGF, sphingosine-1-phosphate, ceramides, purines, serotonin, epinephrine, and vasopressin) [5 ]. These mediators are potent inducers of inflammation, coagulation, angiogenesis, and other endothelial cell-response programs, suggesting that the release of WPB acts as the initiating step in the transition from the quiescent, resting endothelial phenotype to the activated, adhesive endothelium.

Endothelial cell activation is associated with a number of important local and systemic diseases such as atherosclerosis, thrombosis, tumor growth and metastasis, diabetes, retinopathies, and psoriatic skin alterations. It is intriguing that most of these disease processes are restricted to specific vascular beds; e.g., leukocyte adhesion and transmigration are primarily restricted to postcapillary venules. Likewise, platelets adhere primarily in arterial vessels, which are also predilection sites for atherosclerosis [1 ]. Correspondingly, vWF expression and storage in WPB are not uniform in all vessels. Similarly, site-specific metastatic tumor cell dissemination is (among other mechanisms) mediated by the preferential adhesion of metastasizing tumor cells to select organ endothelial cells [6 ]. These observations have stimulated research into the structural and functional analysis of vascular bed, specifically expressed endothelial cell surface molecules, which may serve as vascular bed-specific signaling molecules as well as organ specifically expressed adhesion molecules. For example, a number of endothelial cell specifically expressed cell surface molecules are expressed by angiogenic endothelial cells in the tumor-associated neovasculature. These "tumor endothelial markers" (TEMs) include TEM-1 (endosialin), TEM-5, TEM-7, and TEM-8 [7 8 9 ]. The molecular function of these molecules and their role as signaling or adhesive surface molecules are unknown and await a more detailed, functional analysis.

Inflammatory activation of the vascular endothelium is associated with the cell surface presentation of a number of different adhesion molecules. The respective "activation cocktail" defines the specific proadhesive phenotype of the activated endothelium. The repertoire of surface-expressed adhesion molecules allows the adhesion of selected circulating cell populations. The molecular cascade of events during leukocyte recruitment has been unraveled in great detail during the last two decades. Tethering of leukocytes and subsequent reversible rolling on the endothelium are mediated by the interaction with selectins. L-selectin is expressed by leukocytes and its ligand(s) by the activated endothelium. P-selectin is expressed by the endothelium and stored within WPB. Upon activation, P-selectin can be presented within seconds at the cell surface. Similarly, P-selectin is stored in platelet {alpha}-granules and contributes to thrombus formation. E-selectin is expressed by cytokine-activated endothelial cells and mediates tethering and rolling of leukocytes to the activated endothelium. Following tethering and rolling, leukocytes are activated by chemokines, resulting in integrin activation on their cell surface. These integrins act as receptors for the cell-adhesion molecules ICAM-1, VCAM-1, and mucosal addressin cellular adhesion molecule-1 (MAdCAM-1), which are expressed by endothelial cells in response to inflammatory cytokines, e.g., TNF-{alpha}, IL-1, and also by LPS. This interaction mediates the firm and irreversible adhesion of the leukocytes to the endothelium. Firm adhesion is followed by transendothelial migration and migration into the underlying tissue (for review, see refs. [4 , 10 ]).

The interaction of platelets with the matrix of healthy and injured endothelium is primarily mediated by vWF, synthesized and released from endothelial cells and glycoprotein Ib{alpha} (GPIb{alpha}) expressed by platelets. In addition to vWF, the endothelium deposits in response to injury and inflammation other prothrombic constituents such as collagens, fibronectin, and tissue factor and creates an environment for thrombus formation. It is also well-appreciated that activated platelets release proinflammatory cytokines to modulate vascular inflammation, which may also contribute to the pathogenesis of atherosclerosis [11 , 12 ]. Likewise, platelets have also been shown to stimulate endothelial WPB release, thereby linking thrombus formation and vascular inflammation mechanistically [13 ].

It has become evident in recent years that angiogenesis-regulating vascular receptor tyrosine kinases (RTK) also play important roles in the regulation of endothelial cell activation during inflammation, thrombosis, and tumor metastasis. The emerging roles of the Angiopoietin-Tie system in controlling the quiescent resting state of the endothelium and of the ephrin system in cell-trafficking will be outlined in the following paragraphs.

CONTROL OF VASCULAR HOMEOSTASIS AND REMODELING THROUGH THE ANGIOPOIETIN-TIE SYSTEM

The Angiopoietin-Tie ligand-receptor system (Ang-Tie) was identified in 1996/1997 as the second vascular-specific RTK system (first: VEGF–VEGF receptor), which exerts rate-limiting signaling functions during angiogenesis and vascular remodeling [14 , 15 ]. It consists of two RTK, Tie1 and Tie2, and four corresponding Angiopoietin ligands: Ang-1, Ang-2, Ang-3, and Ang-4 [16 ]. Ang-1 and Ang-2 are the best-characterized ligands, which bind with similar affinity to the same binding site in the extracellular domain of the Tie2 receptor [17 ]. Binding of Ang-1 to Tie2 mediates rapid receptor autophosphorylation, promoting endothelial cell survival and migration, essentially by activation of the protein kinase B/Akt pathway [18 ]. In contrast, Ang-2 does not induce rapid Tie2 autophosphorylation, although it binds with similar affinity to the same site of Tie2, suggesting different regulatory mechanisms of Ang-1 and Ang-2 [16 ].

Ang-1-Tie2 signaling controls the quiescent endothelial cell phenotype
The physiological functions of the Angiopoietins in vivo have largely been deduced from the phenotypes of genetically manipulated loss-of-function and gain-of-function mice. Ang-1- and Tie2-deficient mice have largely complementary, embryonic lethal phenotypes [14 , 19 ]. Tie2-deficient mice die approximately at E10.5 as a consequence of severe defects in vascular remodeling, poor vascular integrity, and perturbed vascular maturation [14 ]. Ang-1-deficient mice have essentially a similar phenotype but die somewhat later during development at E12.5, which might be a result of compensatory mechanisms mediated by other angiopoietins [19 ]. This suggests that Ang-1 is the bona fide agonistic ligand of Tie2, which regulates endothelial cell survival and blood vessel maturation. Constitutive low-level Tie-2 phosphorylation in the adult appears to be required to maintain the mature quiescent phenotype of the resting endothelium (Fig. 1 ) [20 ]. These quiescence-mediating functions correspond to the observation that Ang-1 exerts a vessel-sealing effect, acts anti-inflammatory, and protects against cardiac allograft arteriosclerosis, sepsis, and radiation-induced endothelial cell damage [21 22 23 24 25 ]. Likewise, Ang-1 is a potent inhibitor of VEGF-induced ICAM-1 and VCAM-1 expression in vitro and inflammation-induced permeability in vivo [26 ]. Moreover, Ang-1 prevents VEGF- and TNF-{alpha}-induced tissue factor expression [27 ]. Taken together, low-level constitutive paracrine Ang-1 acts as a gatekeeper of vascular quiescence, maintaining the resting, antithrombotic, and antiadhesive state of the vascular endothelium.


Figure 1
View larger version (39K):
[in this window]
[in a new window]
  		Figure 1. Regulation of vascular quiescence and responsiveness through the Ang-Tie system. The quiescent, resting endothelium (upper) has an antithrombotic and antiadhesive luminal cell surface. Low-level, paracrine-acting Ang-1 [multimeric (white)] induces constitutive Tie2 phosphorylation, which contributes to maintaining the vascular endothelium in the quiescent, resting state. Ang-2 [dimeric (gray)] is stored (with organ and caliber-specific variations) in endothelial cell WPB of the quiescent vasculature. One of the first steps in the cascade of events leading to endothelial cell activation (lower) is the release of the endothelial cell WPBs, which release liberates [among others (see text)], stored Ang-2, shifting the Ang-1/Ang-2 ratio locally in favor of Ang-2, where its release results in endothelial destabilization, yielding the endothelial cell layer responsive to the activities of other cytokines, e.g., proinflammatory stimuli. As such, Ang-2 acts as a built-in, autocrine switch of vascular quiescence and responsiveness.

 
Ang-2 acts as functional antagonist of Ang-1-Tie2 signaling
It is surprising that loss of the Ang-2 gene is compatible with life, as evidenced by the observation that Ang-2-deficient mice are born normally [28 ]. Depending on the genetic background of the mice, a significant fraction of the mice develop a postnatal chylous ascites and die within the first 14 days after birth as a consequence of a mechanistically, hitherto unexplained, lymphatic phenotype [28 ]. The blood vascular system of Ang-2-deficient mice has only minor abnormalities, e.g., perturbed vessel regression of the hyaloid vessels in the eye and dysmorphogenesis of kidney cortical peritubular capillaries [28 , 29 ]. In contrast to the mild phenotype of Ang-2-deficient mice, embryonic overexpression of Ang-2 leads to embryonic lethality, which essentially phenocopies Ang-1- and Tie2-deficient mice [15 ]. This observation supports the concept that Ang-2 acts as the functional antagonistic of Ang-1-mediated Tie2 activation, thereby causing vascular destabilization and loss of the quiescent endothelial phenotype (Fig. 1) . Correspondingly, Ang-2 has been shown to induce vessel regression by destabilizing the contacts between endothelial cells and mural cell in an in vitro coculture model of endothelial cells and smooth muscle cells and in vivo, under physiological conditions, during the regression of the ovarian corpus luteum [30 31 32 ].

Regulation of inflammatory cell trafficking through the Ang-Tie system
Expression profiling studies has identified endothelial cells as the primary source of Ang-2 and a dramatic transcriptional regulation of Ang-2 production upon activation by, e.g., VEGF, fibroblast growth factor-2, and hypoxia [28 , 33 34 35 36 37 ]. Correspondingly, the Ang-2 promoter contains positive and negative regulatory elements, which control endothelial, cell-specific Ang-2 expression [38 ]. Recently, Ang-2 has been identified as a stored molecule of endothelial cell WPBs in cultured blood and lymphatic endothelial cells (ref. [39 ] and U. Fiedler, unpublished data). Correspondingly, granular storage of Ang-2 in WPB can also be detected in vivo in the quiescent vasculature of human tissues with distinct organ-specific and caliber-specific variations. Stored Ang-2 is strongly detectable in the organs of the female reproductive system and in the brain. In contrast, endothelial cells in muscle are largely devoid of stored Ang-2 [40 ], which can be secreted rapidly from endothelial cells by stimulation with multiple secretagogues releasing WPBs [38 ]. Storage in endothelial cells, rapid release, and rapid Ang-2-mediated endothelial cell destabilization suggest that Ang-2 may be an autocrine-acting, negative regulator of endothelial cell quiescence. This concept is supported by recent inflammation experiments in Ang-2-deficient mice [40 ]. Ang-2 null mice cannot elicit a rapid inflammatory response upon abdominal thioglycollate injection or Staphylococcus aureus infection. A detailed analysis of inflammatory leukocyte recruitment revealed that firm leukocyte adhesion, but not leukocyte rolling, is impaired in Ang-2-deficient mice. This suggests that surface presentation of P-selectin from WPBs is not perturbed in these mice. Yet, surface expression of adhesion molecules mediating firm adhesion appears to be impaired. In fact, Ang-2 could be shown to promote adhesion molecule expression by sensitizing endothelial cells toward cytokine-induced adhesion molecule expression [40 ]. Thus, Ang-2 acts as a primer of inflammatory responses and as a critical regulator of vascular homeostasis and responsiveness toward cytokines. The detailed mechanisms by which Ang-2 is priming the endothelium toward cytokine responsiveness await further analysis. These experiments will also unravel the mechanisms through which Ang-2 regulates permeability (endothelial cell–cell contacts) and endothelial cell destabilization (endothelial cell–matrix contacts).

Taken together, the Ang-Tie system is critically involved in the regulation of the quiescent, antithrombotic, and antiadhesive state of the vascular endothelium, and Ang-1 acts anti-inflammatory by inhibiting adhesion molecule expression and permeability, and Ang-2 acts as a primer of fast, inflammatory responses by interfering with Ang-1-Tie2 signaling. Thus, Ang-2 is the dynamic, autocrine regulator of the quiescent state of the endothelium as a result of its storage in WPBs, its rapid release, and its strong transcriptional regulation (Fig. 1) .

Eph RECEPTORS AND EPHRIN LIGANDS AS REGULATORS OF CELL TRAFFICKING

Eph receptors and their corresponding ephrin ligands have been identified as the third vascular RTK system. These molecules have originally been characterized as neuronal guidance molecules [41 42 43 ]. Yet, genetic studies have revealed that B class Eph receptors and B class ephrin ligands exert rate-limiting functions during vascular morphogenic processes [41 42 43 ]. They do so by transducing guidance signals on outgrowing capillary sprouts, which facilitate network formation and proper establishment of an arteriovenous, asymmetrically organized microvasculature. Guidance signals are translated on the cellular level into successive migratory and adhesive events, but the Eph receptors and ephrin ligands are not just expressed by neuronal and vascular wall cells. Instead, the Eph-ephrin system appears to be a rather versatile cell migration and adhesion-controlling molecular system, which is operative in numerous cell populations. This review article focuses on the role of Eph receptors and ephrin ligands in controlling the trafficking of circulating cells. Yet, it is worth mentioning that Eph-ephrin interactions also transmit guidance signals on as diverse cell populations, such as gastrointestinal epithelial cells [44 ], cartilage and bone cells [45 ], and mammary epithelial cells [46 ].

Structure of Eph receptors and ephrin ligands
Eph receptors were first identified in the late 1980s [47 ]. Today, they form the largest subgroup of RTK consisting of 10 A class receptors and six B class receptors [41 42 43 ]. Eph receptors bind their ligands, the ephrins, which are correspondingly classified as A class (six members) and B class (three members). EphrinA ligands are GPI-anchored, peripheral membrane molecules. EphrinB ligands are transmembrane molecules with a short cytoplasmic tail, which itself transduces signals into B class ephrin-expressing cells. B class receptors and B class ligands have multiple, potential phosphorylation sites in their cytoplasmic tail. Likewise, receptors and ligands have a PDZ-binding site at their cytoplasmic C-terminal end. Eph receptor, and ephrin ligand interactions display a significant degree of receptor-ligand promiscuity. Yet, binding is mostly restricted to interactions within the same class of molecules; i.e., A class ephrins bind to A class Eph receptors, whereas B class ephrins bind to B class receptors. So far, only two exceptions to this rule have been described: EphrinA5 can interact with EphB2 and ephrinB ligands can interact with EphA4 [48 49 50 ].

Given that Eph receptors and ephrin ligands are membrane molecules, interactions of receptors and ligands are dependent on the juxtapositional contact of neighboring cells. Signaling occurs following ligand-mediated receptor dimerization. Yet, receptors and ligands are also capable of clustering to form higher-order receptor-ligand complexes [51 , 52 ]. The degree of receptor clustering is dependent on the density of surface receptor expression [53 ]. Eph-ephrin signaling occurs classically in trans between two neighboring cells. Yet, it has also been reported more recently that cis signaling can lead to receptor activation on the same receptor and ligand-expressing cell [54 ].

Signaling through Eph receptors and ephrin ligands
Eph receptors are phosphorylated upon ephrin binding by transphosphorylation, acting as classical RTK, but they can also be phosphorylated by Src-family kinases [55 , 56 ], which with respective phosphatases, promote signaling through the cytoplasmic tail of ephrinB ligands [57 ]. The downstream signaling of Eph receptors and ephrin ligands occurs predominately through molecules that contain Src homology 2 domains [58 , 59 ]. In addition, there are PDZ domain-containing proteins and Rho family guanine nucleotide-exchange factors, which mediate diverse downstream signaling events [60 ]. The ubiquitin ligase Cbl is important for protein degradation after internalization [61 , 62 ] and is also involved in the regulation of EphA receptor expression [63 ]. EphrinA ligands have been demonstrated to be cleaved by a Kuzbanian metalloprotease (ADAM10) [63 , 64 ]. Similarly, cleavage of ephrinB molecules has also been proposed [65 ]. Functionally, forward Eph receptor signaling and reverse ephrin signaling transduce positional guidance cues on cells. These may be attractive or repulsive. On the cellular level, guidance cues are translated into migratory and adhesive events [42 , 59 , 66 , 67 ].

Regulation of circulating cell trafficking by Eph receptors and ephrin ligands
Eph receptors and ephrin ligands have originally been described as neuron-specific molecules, which mediate attractive and repulsive guidance signals on outgrowing neurons [42 , 59 , 66 , 67 ]. It is surprising that genetic experiments identified B class Eph receptors and B class ephrin ligands as rate-limiting regulators of vascular morphogenesis. The phenotype of EphB4-deficient and ephrinB-deficient mice is characterized by early embryonic lethality with an inability to properly position arteries and veins toward each other. As such, mice with targeted mutations of EphB4 or ephrinB2 are not capable of properly assembling the growing vascular network and establishing directional, arteriovenous blood flow [68 69 70 71 ]. EphB4 is preferentially expressed by venous endothelial cells, whereas ephrinB2 is almost exclusively expressed by arterial and angiogenic endothelial cells [72 , 73 ]. These studies have also shown that smooth muscle cells and pericytes express EphB receptor and ephrinB ligands. Correspondingly, the requirement of smooth muscle cell-expressed ephrinB2 for normal vessel development has recently been demonstrated through conditional gene-inactivation experiments [74 ].

The arteriovenous, asymmetric expression of EphB4 and ephrinB2 has stimulated research into the identification of arteriovenously expressed molecules and the molecular and genetic mechanisms of arteriovenous differentiation. Genetic experiments in zebrafish suggest that arterial and venous fate determination occurs early during development, probably even prior to the formation of arteries and veins [75 ]. This may suggest that arterial and venous endothelial cell differentiation is an intrinsic property of the cells. Indeed, cultured arterial and venous endothelial cells appear to maintain some of their intrinsic, arteriovenous properties [76 ]. Yet, arterial ephrinB2 expression does not appear to be an intrinsic property of arterial endothelial cells. Instead, arteriovenous asymmetric ephrinB2 expression is rapidly lost upon transfer in culture of arterial and venous endothelial cells. This observed arteriovenous dedifferentiation has stimulated research into the mechanisms and microenvironmental milieu factors, which control arterial ephrinB2 expression. These studies have identified stimulation by VEGF, contact with smooth muscle cells, and fluid shear stress as regulators of endothelial cell ephrinB2 expression [77 78 79 80 ].

The ubiquitous expression of Eph receptors and ephrin ligands {among others: neuronal cells, endothelial cells, smooth muscle cells, pericytes, epithelial cells, tumor cells, circulating hematopoietic cells [T cell, platelets, dendritic cells (DC), monocytes/macrophages, B cells]} suggests much broader roles of Eph-ephrin signaling in transducing positional guidance cues among multiple contacting cell populations. A significant number of publications have been presented in recent years supporting the concept that Eph-ephrin interactions control the trafficking of circulating cells (Table 1 ). They do so by acting as adhesion molecules themselves as well as by modulating the activity of other adhesion molecules.


View this table:
[in this window]
[in a new window]
  		Table 1. Regulation of Circulating Cell Functions by Eph Receptor and Ephrin Ligand Interactions

 
T cells express Eph receptors and ephrin ligands. It is most notable that high levels of EphB6 mRNA were detected in the thymus [96 ]. All three ephrinB ligands play a role in controlling the interactions of T cells. For example, ephrinB1 is essential in T cell–T cell cooperation during T cell activation [86 ]. EphrinB2 and ephrinB3 also play an important role in the immune system by costimulating T cells [87 ] and enhancing T cell signaling [93 ]. EphB6 null mice have altered T cell functions [93 ], and the interaction of EphB6 with its corresponding ligands facilitates T cell responses to antigens [90 , 105 ]. EphrinA1 signaling is capable of suppressing Th2 cell activation and therefore, exerts pivotal T cell functions [82 ]. EphA receptor signaling has also been reported during thymocyte development [83 ].

The Eph-ephrin system also has a major role in the activation of platelets [106 ]. It has been reported that platelets express EphA4, EphB1, and ephrinB1 and that these molecules support the aggregation of platelets [104 ]. This process appears to be dependent on Eph receptor forward signaling, as ephrinB1 reverse signaling is not involved in platelet activation [103 ]. Similarly, EphA4 or ephrinB1 promotes integrin-mediated adhesion of platelets to fibrinogen [102 ].

Expression and functional effects of EphA family members have been detected in Langerhans-like dendritic cells (DC) [99 ]. EphA receptors are important for DC trafficking by regulating the adhesion to fibronectin [100 ]. EphB1 is expressed by plasmacytoid DC (PDC) and monocyte-derived DC (MDDC) [101 ]. B lymphocytes secrete ephrinA4, and it has been proposed to interact with DC in human tonsils [97 ]. The regulation of EphA7 during B lymphopoiesis points to a functional role of EphA7 in B cell differentiation [98 ]. Lastly, EphB4 expressing hematopoietic progenitors have been shown to differentiate to erythrocytes in the presence of erythropoietin and ephrinB2, suggesting an important role of ephrinB2 during erythropoiesis [107 ].

PERSPECTIVE

Vascular RTK have been identified as morphogenic signaling systems, which control the growth, assembly, and maturation of the vascular network during developmental and adult angiogenesis. The recognition that the same morphogenic molecules exert homeostatic maintenance functions in the adult marks an important change of paradigm. Future work will shed further light into the complexity of adult vascular RTK functions and likely unravel further surprises, which may expand the therapeutic range of vascular RTK-modulating drugs beyond angiogenesis-related applications.

Received November 13, 2005; revised June 22, 2006; accepted June 26, 2006.

REFERENCES

  1. Cines, D. B., Pollak, E. S., Buck, C. A., Loscalzo, J., Zimmerman, G. A., McEver, R. P., Pober, J. S., Wick, T. M., Konkle, B. A., Schwartz, B. S., Barnathan, E. S., McCrae, K. R., Hug, B. A., Schmidt, A. M., Stern, D. M. (1998) Endothelial cells in physiology and in the pathophysiology of vascular disorders Blood 91,3527-3561[Free Full Text]
  2. Gowans, J. L. (1959) The recirculation of lymphocytes from blood to lymph in the rat J. Physiol. 146,54-69[Free Full Text]
  3. Majno, G., Palade, G. E., Schoefl, G. I. (1961) Studies on inflammation. II. The site of action of histamine and serotonin along the vascular tree: a topographic study J. Biophys. Biochem. Cytol. 11,607-626[Medline]
  4. Johnson-Leger, C., Imhof, B. A. (2003) Forging the endothelium during inflammation: pushing at a half-open door? Cell Tissue Res. 314,93-105[CrossRef][Medline]
  5. Rondaij, M. G., Bierings, R., Kragt, A., van Mourik, J. A., Voorberg, J. (2006) Dynamics and plasticity of Weibel-Palade bodies in endothelial cells Arterioscler. Thromb. Vasc. Biol. 26,1002-1007[Abstract/Free Full Text]
  6. Zetter, B. R. (1997) On target with tumor blood vessel markers Nat. Biotechnol. 15,1243-1244[CrossRef][Medline]
  7. Christian, S., Ahorn, H., Koehler, A., Eisenhaber, F., Rodi, H. P., Garin-Chesa, P., Park, J. E., Rettig, W. J., Lenter, M. C. (2001) Molecular cloning and characterization of endosialin, a C-type lectin-like cell surface receptor of tumor endothelium J. Biol. Chem. 276,7408-7414[Abstract/Free Full Text]
  8. St Croix, B., Rago, C., Velculescu, V., Traverso, G., Romans, K. E., Montgomery, E., Lal, A., Riggins, G. J., Lengauer, C., Vogelstein, B., Kinzler, K. W. (2000) Genes expressed in human tumor endothelium Science 289,1197-1202[Abstract/Free Full Text]
  9. Nanda, A., Carson-Walter, E. B., Seaman, S., Barber, T. D., Stampfl, J., Singh, S., Vogelstein, B., Kinzler, K. W., St Croix, B. (2004) TEM8 interacts with the cleaved C5 domain of collagen {alpha} 3(VI) Cancer Res. 64,817-820[Abstract/Free Full Text]
  10. Liu, Y., Shaw, S. K., Ma, S., Yang, L., Luscinskas, F. W., Parkos, C. A. (2004) Regulation of leukocyte transmigration: cell surface interactions and signaling events J. Immunol. 172,7-13[Free Full Text]
  11. Ruggeri, Z. M. (2002) Platelets in atherothrombosis Nat. Med. 8,1227-1234[CrossRef][Medline]
  12. Libby, P. (2002) Inflammation in atherosclerosis Nature 420,868-874[CrossRef][Medline]
  13. Dole, V. S., Bergmeier, W., Mitchell, H. A., Eichenberger, S. C., Wagner, D. D. (2005) Activated platelets induce Weibel-Palade-body secretion and leukocyte rolling in vivo: role of P-selectin Blood 106,2334-2339[Abstract/Free Full Text]
  14. Suri, C., Jones, P. F., Patan, S., Bartunkova, S., Maisonpierre, P. C., Davis, S., Sato, T. N., Yancopoulos, G. D. (1996) Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis Cell 87,1171-1180[CrossRef][Medline]
  15. Maisonpierre, P. C., Suri, C., Jones, P. F., Bartunkova, S., Wiegand, S. J., Radziejewski, C., Compton, D., McClain, J., Aldrich, T. H., Papadopoulos, N., Daly, T. J., Davis, S., Sato, T. N., Yancopoulos, G. D. (1997) Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis Science 277,55-60[Abstract/Free Full Text]
  16. Gale, N. W., Yancopoulos, G. D. (1999) Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development Genes Dev. 13,1055-1066[Free Full Text]
  17. Fiedler, U., Krissl, T., Koidl, S., Weiss, C., Koblizek, T., Deutsch, U., Martiny-Baron, G., Marme, D., Augustin, H. G. (2003) Angiopoietin-1 and angiopoietin-2 share the same binding domains in the Tie-2 receptor involving the first Ig-like loop and the epidermal growth factor-like repeats J. Biol. Chem. 278,1721-1727[Abstract/Free Full Text]
  18. Daly, C., Wong, V., Burova, E., Wei, Y., Zabski, S., Griffiths, J., Lai, K. M., Lin, H. C., Ioffe, E., Yancopoulos, G. D., Rudge, J. S. (2004) Angiopoietin-1 modulates endothelial cell function and gene expression via the transcription factor FKHR (FOXO1) Genes Dev. 18,1060-1071[Abstract/Free Full Text]
  19. Davis, S., Aldrich, T. H., Jones, P. F., Acheson, A., Compton, D. L., Jain, V., Ryan, T. E., Bruno, J., Radziejewski, C., Maisonpierre, P. C., Yancopoulos, G. D. (1996) Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning Cell 87,1161-1169[CrossRef][Medline]
  20. Wong, A. L., Haroon, Z. A., Werner, S., Dewhirst, M. W., Greenberg, C. S., Peters, K. G. (1997) Tie2 expression and phosphorylation in angiogenic and quiescent adult tissues Circ. Res. 81,567-574[Abstract/Free Full Text]
  21. Thurston, G., Rudge, J. S., Ioffe, E., Zhou, H., Ross, L., Croll, S. D., Glazer, N., Holash, J., McDonald, D. M., Yancopoulos, G. D. (2000) Angiopoietin-1 protects the adult vasculature against plasma leakage Nat. Med. 6,460-463[CrossRef][Medline]
  22. Jeon, B. H., Khanday, F., Deshpande, S., Haile, A., Ozaki, M., Irani, K. (2003) Tie-ing the antiinflammatory effect of angiopoietin-1 to inhibition of NF-{kappa}B Circ. Res. 92,586-588[Free Full Text]
  23. Nykanen, A. I., Krebs, R., Saaristo, A., Turunen, P., Alitalo, K., Yla-Herttuala, S., Koskinen, P. K., Lemstrom, K. B. (2003) Angiopoietin-1 protects against the development of cardiac allograft arteriosclerosis Circulation 107,1308-1314[Abstract/Free Full Text]
  24. Witzenbichler, B., Westermann, D., Knueppel, S., Schultheiss, H. P., Tschope, C. (2005) Protective role of angiopoietin-1 in endotoxic shock Circulation 111,97-105[Abstract/Free Full Text]
  25. Kwak, H. J., Lee, S. J., Lee, Y. H., Ryu, C. H., Koh, K. N., Choi, H. Y., Koh, G. Y. (2000) Angiopoietin-1 inhibits irradiation- and mannitol-induced apoptosis in endothelial cells Circulation 101,2317-2324[Abstract/Free Full Text]
  26. Kim, I., Moon, S. O., Park, S. K., Chae, S. W., Koh, G. Y. (2001) Angiopoietin-1 reduces VEGF-stimulated leukocyte adhesion to endothelial cells by reducing ICAM-1, VCAM-1, and E-selectin expression Circ. Res. 89,477-479[Abstract/Free Full Text]
  27. Kim, I., Oh, J. L., Ryu, Y. S., So, J. N., Sessa, W. C., Walsh, K., Koh, G. Y. (2002) Angiopoietin-1 negatively regulates expression and activity of tissue factor in endothelial cells FASEB J. 16,126-128[Abstract/Free Full Text]
  28. Gale, N. W., Thurston, G., Hackett, S. F., Renard, R., Wang, Q., McClain, J., Martin, C., Witte, C., Witte, M. H., Jackson, D., Suri, C., Campochiaro, P. A., Wiegand, S. J., Yancopoulos, G. D. (2002) Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1 Dev. Cell 3,411-423[CrossRef][Medline]
  29. Pitera, J. E., Woolf, A. S., Gale, N. W., Yancopoulos, G. D., Yuan, H. T. (2004) Dysmorphogenesis of kidney cortical peritubular capillaries in angiopoietin-2-deficient mice Am. J. Pathol. 165,1895-1906[Abstract/Free Full Text]
  30. Scharpfenecker, M., Fiedler, U., Reiss, Y., Augustin, H. G. (2005) The Tie-2 ligand Angiopoietin-2 destabilizes quiescent endothelium through an internal autocrine loop mechanism J. Cell Sci. 118,771-780[Abstract/Free Full Text]
  31. Lobov, I. B., Brooks, P. C., Lang, R. A. (2002) Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo Proc. Natl. Acad. Sci. USA 99,11205-11210[Abstract/Free Full Text]
  32. Goede, V., Schmidt, T., Kimmina, S., Kozian, D., Augustin, H. G. (1998) Analysis of blood vessel maturation processes during cyclic ovarian angiogenesis Lab. Invest. 78,1385-1394[Medline]
  33. Hackett, S. F., Wiegand, S., Yancopoulos, G., Campochiaro, P. A. (2002) Angiopoietin-2 plays an important role in retinal angiogenesis J. Cell. Physiol. 192,182-187[CrossRef][Medline]
  34. Holash, J., Maisonpierre, P. C., Compton, D., Boland, P., Alexander, C. R., Zagzag, D., Yancopoulos, G. D., Wiegand, S. J. (1999) Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF Science 284,1994-1998[Abstract/Free Full Text]
  35. Huang, Y. Q., Li, J. J., Hu, L., Lee, M., Karpatkin, S. (2002) Thrombin induces increased expression and secretion of angiopoietin-2 from human umbilical vein endothelial cells Blood 99,1646-1650[Abstract/Free Full Text]
  36. Mandriota, S. J., Pepper, M. S. (1998) Regulation of angiopoietin-2 mRNA levels in bovine microvascular endothelial cells by cytokines and hypoxia Circ. Res. 83,852-859[Medline]
  37. Stratmann, A., Risau, W., Plate, K. H. (1998) Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis Am. J. Pathol. 153,1459-1466[Abstract/Free Full Text]
  38. Hegen, A., Koidl, S., Weindel, K., Marme, D., Augustin, H. G., Fiedler, U. (2004) Expression of angiopoietin-2 in endothelial cells is controlled by positive and negative regulatory promoter elements Arterioscler. Thromb. Vasc. Biol. 24,1803-1809[Abstract/Free Full Text]
  39. Fiedler, U., Scharpfenecker, M., Koidl, S., Hegen, A., Grunow, V., Schmidt, J. M., Kriz, W., Thurston, G., Augustin, H. G. (2004) The Tie-2 ligand Angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies Blood 103,4150-4156[Abstract/Free Full Text]
  40. Fiedler, U., Reiss, Y., Scharpfenecker, M., Grunow, V., Koidl, S., Thurston, G., Gale, N. W., Witzenrath, M., Rosseau, S., Suttorp, N., Sobke, A., Herrmann, M., Preissner, K. T., Vajkoczy, P., Augustin, H. G. (2006) Angiopoietin-2 sensitizes endothelial cells to TNF-{alpha} and has a crucial role in the induction of inflammation Nat. Med. 12,235-239[CrossRef][Medline]
  41. . Eph Nomenclature Committee (1997) Unified nomenclature for Eph family receptors and their ligands, the ephrins Cell 90,403-404[CrossRef][Medline]
  42. Flanagan, J. G., Vanderhaeghen, P. (1998) The ephrins and Eph receptors in neural development Annu. Rev. Neurosci. 21,309-345[CrossRef][Medline]
  43. Palmer, A., Klein, R. (2003) Multiple roles of ephrins in morphogenesis, neuronal networking, and brain function Genes Dev. 17,1429-1450[Free Full Text]
  44. Batlle, E., Henderson, J. T., Beghtel, H., van den Born, M. M., Sancho, E., Huls, G., Meeldijk, J., Robertson, J., van de Wetering, M., Pawson, T., Clevers, H. (2002) ß-Catenin and TCF mediate cell positioning in the intestinal epithelium by controlling the expression of EphB/ephrinB Cell 111,251-263[CrossRef][Medline]
  45. Compagni, A., Logan, M., Klein, R., Adams, R. H. (2003) Control of skeletal patterning by ephrinB1-EphB interactions Dev. Cell 5,217-230[CrossRef][Medline]
  46. Munarini, N., Jager, R., Abderhalden, S., Zuercher, G., Rohrbach, V., Loercher, S., Pfanner-Meyer, B., Andres, A. C., Ziemiecki, A. (2002) Altered mammary epithelial development, pattern formation and involution in transgenic mice expressing the EphB4 receptor tyrosine kinase J. Cell Sci. 115,25-37[Abstract/Free Full Text]
  47. Hirai, H., Maru, Y., Hagiwara, K., Nishida, J., Takaku, F. (1987) A novel putative tyrosine kinase receptor encoded by the Eph gene Science 238,1717-1720[Abstract/Free Full Text]
  48. Pasquale, E. B. (2004) Eph-ephrin promiscuity is now crystal clear Nat. Neurosci. 7,417-418[CrossRef][Medline]
  49. Gale, N. W., Holland, S. J., Valenzuela, D. M., Flenniken, A., Pan, L., Ryan, T. E., Henkemeyer, M., Strebhardt, K., Hirai, H., Wilkinson, D. G., Pawson, T., Davis, S., Yancopoulos, G. D. (1996) Eph receptors and ligands comprise two major specificity subclasses and are reciprocally compartmentalized during embryogenesis Neuron 17,9-19[CrossRef][Medline]
  50. Himanen, J. P., Chumley, M. J., Lackmann, M., Li, C., Barton, W. A., Jeffrey, P. D., Vearing, C., Geleick, D., Feldheim, D. A., Boyd, A. W., Henkemeyer, M., Nikolov, D. B. (2004) Repelling class discrimination: Ephrin-A5 binds to and activates EphB2 receptor signaling Nat. Neurosci. 7,501-509[CrossRef][Medline]
  51. Poliakov, A., Cotrina, M., Wilkinson, D. G. (2004) Diverse roles of Eph receptors and ephrins in the regulation of cell migration and tissue assembly Dev. Cell 7,465-480[CrossRef][Medline]
  52. Himanen, J. P., Nikolov, D. B. (2003) Eph signaling: a structural view Trends Neurosci. 26,46-51[CrossRef][Medline]
  53. Smith, F. M., Vearing, C., Lackmann, M., Treutlein, H., Himanen, J., Chen, K., Saul, A., Nikolov, D., Boyd, A. W. (2004) Dissecting the EphA3/Ephrin-A5 interactions using a novel functional mutagenesis screen J. Biol. Chem. 279,9522-9531[Abstract/Free Full Text]
  54. Yin, Y., Yamashita, Y., Noda, H., Okafuji, T., Go, M. J., Tanaka, H. (2004) EphA receptor tyrosine kinases interact with co-expressed ephrin-A ligands in cis Neurosci. Res. 48,285-296[CrossRef][Medline]
  55. Kalo, M. S., Pasquale, E. B. (1999) Signal transfer by Eph receptors Cell Tissue Res. 298,1-9[CrossRef][Medline]
  56. Knoll, B., Drescher, U. (2004) Src family kinases are involved in EphA receptor-mediated retinal axon guidance J. Neurosci. 24,6248-6257[Abstract/Free Full Text]
  57. Palmer, A., Zimmer, M., Erdmann, K. S., Eulenburg, V., Porthin, A., Heumann, R., Deutsch, U., Klein, R. (2002) EphrinB phosphorylation and reverse signaling: regulation by Src kinases and PTP-BL phosphatase Mol. Cell 9,725-737[CrossRef][Medline]
  58. Murai, K. K., Pasquale, E. B. (2003) "Eph"ective signaling: forward, reverse and crosstalk J. Cell Sci. 116,2823-2832[Abstract/Free Full Text]
  59. Kullander, K., Klein, R. (2002) Mechanisms and functions of Eph and ephrin signaling Nat. Rev. Mol. Cell Biol. 3,475-486[CrossRef][Medline]
  60. Noren, N. K., Lu, M., Freeman, A. L., Koolpe, M., Pasquale, E. B. (2004) Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth Proc. Natl. Acad. Sci. USA 101,5583-5588[Abstract/Free Full Text]
  61. Walker-Daniels, J., Riese, D. J., II, Kinch, M. S. (2002) c-Cbl-dependent EphA2 protein degradation is induced by ligand binding Mol. Cancer Res. 1,79-87[Abstract/Free Full Text]
  62. Wang, Y., Ota, S., Kataoka, H., Kanamori, M., Li, Z., Band, H., Tanaka, M., Sugimura, H. (2002) Negative regulation of EphA2 receptor by Cbl Biochem. Biophys. Res. Commun. 296,214-220[CrossRef][Medline]
  63. Sharfe, N., Freywald, A., Toro, A., Roifman, C. M. (2003) Ephrin-A1 induces c-Cbl phosphorylation and EphA receptor down-regulation in T cells J. Immunol. 170,6024-6032[Abstract/Free Full Text]
  64. Hattori, M., Osterfield, M., Flanagan, J. G. (2000) Regulated cleavage of a contact-mediated axon repellent Science 289,1360-1365[Abstract/Free Full Text]
  65. Pascall, J. C., Brown, K. D. (2004) Intramembrane cleavage of ephrinB3 by the human rhomboid family protease, RHBDL2 Biochem. Biophys. Res. Commun. 317,244-252[CrossRef][Medline]
  66. Wilkinson, D. G. (2001) Multiple roles of EPH receptors and ephrins in neural development Nat. Rev. Neurosci. 2,155-164[Medline]
  67. Pasquale, E. B. (2005) Eph receptor signaling casts a wide net on cell behavior Nat. Rev. Mol. Cell Biol. 6,462-475[CrossRef][Medline]
  68. Wang, H. U., Chen, Z. F., Anderson, D. J. (1998) Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4 Cell 93,741-753[CrossRef][Medline]
  69. Adams, R. H., Wilkinson, G. A., Weiss, C., Diella, F., Gale, N. W., Deutsch, U., Risau, W., Klein, R. (1999) Roles of ephrinB ligands and EphB receptors in cardiovascular development: demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis Genes Dev. 13,295-306[Abstract/Free Full Text]
  70. Gerety, S. S., Wang, H. U., Chen, Z. F., Anderson, D. J. (1999) Symmetrical mutant phenotypes of the receptor EphB4 and its specific transmembrane ligand ephrin-B2 in cardiovascular development Mol. Cell 4,403-414[CrossRef][Medline]
  71. Adams, R. H., Diella, F., Hennig, S., Helmbacher, F., Deutsch, U., Klein, R. (2001) The cytoplasmic domain of the ligand ephrinB2 is required for vascular morphogenesis but not cranial neural crest migration Cell 104,57-69[CrossRef][Medline]
  72. Shin, D., Garcia-Cardena, G., Hayashi, S., Gerety, S., Asahara, T., Stavrakis, G., Isner, J., Folkman, J., Gimbrone, M. A., Jr, Anderson, D. J. (2001) Expression of ephrinB2 identifies a stable genetic difference between arterial and venous vascular smooth muscle as well as endothelial cells, and marks subsets of microvessels at sites of adult neovascularization Dev. Biol. 230,139-150[CrossRef][Medline]
  73. Gale, N. W., Baluk, P., Pan, L., Kwan, M., Holash, J., DeChiara, T. M., McDonald, D. M., Yancopoulos, G. D. (2001) Ephrin-B2 selectively marks arterial vessels and neovascularization sites in the adult, with expression in both endothelial and smooth-muscle cells Dev. Biol. 230,151-160[CrossRef][Medline]
  74. Foo, S. S., Turner, C. J., Adams, S., Compagni, A., Aubyn, D., Kogata, N., Lindblom, P., Shani, M., Zicha, D., Adams, R. H. (2006) Ephrin-B2 controls cell motility and adhesion during blood-vessel-wall assembly Cell 124,161-173[CrossRef][Medline]
  75. Zhong, T. P., Rosenberg, M., Mohideen, M. A., Weinstein, B., Fishman, M. C. (2000) Gridlock, an HLH gene required for assembly of the aorta in zebrafish Science 287,1820-1824[Abstract/Free Full Text]
  76. Chi, J. T., Chang, H. Y., Haraldsen, G., Jahnsen, F. L., Troyanskaya, O. G., Chang, D. S., Wang, Z., Rockson, S. G., van de Rijn, M., Botstein, D., Brown, P. O. (2003) Endothelial cell diversity revealed by global expression profiling Proc. Natl. Acad. Sci. USA 100,10623-10628[Abstract/Free Full Text]
  77. Korff, T., Dandekar, G., Pfaff, D., Fuller, T., Goettsch, W., Morawietz, H., Schaffner, F., Augustin, H. G. (2006) Endothelial ephrinB2 is controlled by microenvironmental determinants and associates context-dependently with CD31 Arterioscler. Thromb. Vasc. Biol. 26,468-474[Abstract/Free Full Text]
  78. Goettsch, W., Augustin, H. G., Morawietz, H. (2004) Down-regulation of endothelial ephrinB2 expression by laminar shear stress Endothelium 11,259-265[CrossRef][Medline]
  79. Mukouyama, Y. S., Shin, D., Britsch, S., Taniguchi, M., Anderson, D. J. (2002) Sensory nerves determine the pattern of arterial differentiation and blood vessel branching in the skin Cell 109,693-705[CrossRef][Medline]
  80. Le Noble, F., Moyon, D., Pardanaud, L., Yuan, L., Djonov, V., Matthijsen, R., Breant, C., Fleury, V., Eichmann, A. (2004) Flow regulates arterial-venous differentiation in the chick embryo yolk sac Development 131,361-375[Abstract/Free Full Text]
  81. Aasheim, H. C., Delabie, J., Finne, E. F. (2005) Ephrin-A1 binding to CD4+ T lymphocytes stimulates migration and induces tyrosine phosphorylation of PYK2 Blood 105,2869-2876[Abstract/Free Full Text]
  82. Wohlfahrt, J. G., Karagiannidis, C., Kunzmann, S., Epstein, M. M., Kempf, W., Blaser, K., Schmidt-Weber, C. B. (2004) Ephrin-A1 suppresses Th2 cell activation and provides a regulatory link to lung epithelial cells J. Immunol. 172,843-850[Abstract/Free Full Text]
  83. Munoz, J. J., Alonso, C. L., Sacedon, R., Crompton, T., Vicente, A., Jimenez, E., Varas, A., Zapata, A. G. (2002) Expression and function of the Eph A receptors and their ligands ephrins A in the rat thymus J. Immunol. 169,177-184[Abstract/Free Full Text]
  84. Sharfe, N., Freywald, A., Toro, A., Dadi, H., Roifman, C. (2002) Ephrin stimulation modulates T cell chemotaxis Eur. J. Immunol. 32,3745-3755[CrossRef][Medline]
  85. Smith, L. M., Walsh, P. T., Rudiger, T., Cotter, T. G., Mc Carthy, T. V., Marx, A., O’Connor, R. (2004) EphA3 is induced by CD28 and IGF-1 and regulates cell adhesion Exp. Cell Res. 292,295-303[CrossRef][Medline]
  86. Yu, G., Luo, H., Wu, Y., Wu, J. (2004) EphrinB1 is essential in T-cell–T-cell co-operation during T-cell activation J. Biol. Chem. 279,55531-55539[Abstract/Free Full Text]
  87. Yu, G., Luo, H., Wu, Y., Wu, J. (2003) Ephrin B2 induces T cell costimulation J. Immunol. 171,106-114[Abstract/Free Full Text]
  88. Yu, G., Luo, H., Wu, Y., Wu, J. (2003) Mouse ephrinB3 augments T-cell signaling and responses to T-cell receptor ligation J. Biol. Chem. 278,47209-47216[Abstract/Free Full Text]
  89. Freywald, A., Sharfe, N., Rashotte, C., Grunberger, T., Roifman, C. M. (2003) The EphB6 receptor inhibits JNK activation in T lymphocytes and modulates T cell receptor-mediated responses J. Biol. Chem. 278,10150-10156[Abstract/Free Full Text]
  90. Luo, H., Yu, G., Wu, Y., Wu, J. (2002) EphB6 crosslinking results in costimulation of T cells J. Clin. Invest. 110,1141-1150[CrossRef][Medline]
  91. Shimoyama, M., Matsuoka, H., Nagata, A., Iwata, N., Tamekane, A., Okamura, A., Gomyo, H., Ito, M., Jishage, K., Kamada, N., Suzuki, H., Tetsuo Noda, T., Matsui, T. (2002) Developmental expression of EphB6 in the thymus: lessons from EphB6 knockout mice Biochem. Biophys. Res. Commun. 298,87-94[CrossRef][Medline]
  92. Shimoyama, M., Matsuoka, H., Tamekane, A., Ito, M., Iwata, N., Inoue, R., Chihara, K., Furuya, A., Hanai, N., Matsui, T. (2000) T-cell-specific expression of kinase-defective Eph-family receptor protein, EphB6 in normal as well as transformed hematopoietic cells Growth Factors 18,63-78[Medline]
  93. Luo, H., Yu, G., Tremblay, J., Wu, J. (2004) EphB6-null mutation results in compromised T cell function J. Clin. Invest. 114,1762-1773[CrossRef][Medline]
  94. Luo, H., Wan, X., Wu, Y., Wu, J. (2001) Cross-linking of EphB6 resulting in signal transduction and apoptosis in Jurkat cells J. Immunol. 167,1362-1370[Abstract/Free Full Text]
  95. Freywald, A., Sharfe, N., Roifman, C. M. (2002) The kinase-null EphB6 receptor undergoes transphosphorylation in a complex with EphB1 J. Biol. Chem. 277,3823-3828[Abstract/Free Full Text]
  96. Gurniak, C. B., Berg, L. J. (1996) A new member of the Eph family of receptors that lacks protein tyrosine kinase activity Oncogene 13,777-786[Medline]
  97. Aasheim, H. C., Munthe, E., Funderud, S., Smeland, E. B., Beiske, K., Logtenberg, T. (2000) A splice variant of human ephrin-A4 encodes a soluble molecule that is secreted by activated human B lymphocytes Blood 95,221-230[Abstract/Free Full Text]
  98. Aasheim, H. C., Terstappen, L. W., Logtenberg, T. (1997) Regulated expression of the Eph-related receptor tyrosine kinase Hek11 in early human B lymphopoiesis Blood 90,3613-3622[Abstract/Free Full Text]
  99. Munthe, E., Finne, E. F., Aasheim, H. C. (2004) Expression and functional effects of Eph receptor tyrosine kinase A family members on Langerhans-like dendritic cells BMC Immunol. 5,9[CrossRef][Medline]
  100. De Saint-Vis, B., Bouchet, C., Gautier, G., Valladeau, J., Caux, C., Garrone, P. (2003) Human dendritic cells express neuronal Eph receptor tyrosine kinases: role of EphA2 in regulating adhesion to fibronectin Blood 102,4431-4440[Abstract/Free Full Text]
  101. Rissoan, M. C., Duhen, T., Bridon, J. M., Bendriss-Vermare, N., Peronne, C., de Saint Vis, B., Briere, F., Bates, E. E. (2002) Subtractive hybridization reveals the expression of immunoglobulin-like transcript 7, Eph-B1, granzyme B, and 3 novel transcripts in human plasmacytoid dendritic cells Blood 100,3295-3303[Abstract/Free Full Text]
  102. Prevost, N., Woulfe, D. S., Jiang, H., Stalker, T. J., Marchese, P., Ruggeri, Z. M., Brass, L. F. (2005) Eph kinases and ephrins support thrombus growth and stability by regulating integrin outside-in signaling in platelets Proc. Natl. Acad. Sci. USA 102,9820-9825[Abstract/Free Full Text]
  103. Prevost, N., Woulfe, D. S., Tognolini, M., Tanaka, T., Jian, W., Fortna, R. R., Jiang, H., Brass, L. F. (2004) Signaling by ephrinB1 and Eph kinases in platelets promotes Rap1 activation, platelet adhesion, and aggregation via effector pathways that do not require phosphorylation of ephrinB1 Blood 103,1348-1355[Abstract/Free Full Text]
  104. Prevost, N., Woulfe, D., Tanaka, T., Brass, L. F. (2002) Interactions between Eph kinases and ephrins provide a mechanism to support platelet aggregation once cell-to-cell contact has occurred Proc. Natl. Acad. Sci. USA 99,9219-9224[Abstract/Free Full Text]
  105. Wu, J., Luo, H. (2005) Recent advances on T-cell regulation by receptor tyrosine kinases Curr. Opin. Hematol. 12,292-297[CrossRef][Medline]
  106. Prevost, N., Woulfe, D., Tognolini, M., Brass, L. F. (2003) Contact-dependent signaling during the late events of platelet activation J. Thromb. Haemost. 1,1613-1627[CrossRef][Medline]
  107. Suenobu, S., Takakura, N., Inada, T., Yamada, Y., Yuasa, H., Zhang, X. Q., Sakano, S., Oike, Y., Suda, T. (2002) A role of EphB4 receptor and its ligand, ephrin-B2, in erythropoiesis Biochem. Biophys. Res. Commun. 293,1124-1131[CrossRef][Medline]



This article has been cited by other articles:


Home page
 J. Cell Sci.Home page
D. Pfaff, M. Heroult, M. Riedel, Y. Reiss, R. Kirmse, T. Ludwig, T. Korff, M. Hecker, and H. G. Augustin
Involvement of endothelial ephrin-B2 in adhesion and transmigration of EphB-receptor-expressing monocytes
J. Cell Sci., November 15, 2008; 121(22): 3842 - 3850.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
R. Becker, M. C. Lenter, T. Vollkommer, A. M. Boos, D. Pfaff, H. G. Augustin, and S. Christian
Tumor stroma marker endosialin (Tem1) is a binding partner of metastasis-related protein Mac-2 BP/90K
FASEB J, August 1, 2008; 22(8): 3059 - 3067.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. Korff, J. Braun, D. Pfaff, H. G. Augustin, and M. Hecker
Role of ephrinB2 expression in endothelial cells during arteriogenesis: impact on smooth muscle cell migration and monocyte recruitment
Blood, July 1, 2008; 112(1): 73 - 81.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
A.-C. Gerard, S. Poncin, B. Caetano, P. Sonveaux, J.-N. Audinot, O. Feron, I. M. Colin, and F. Soncin
Iodine Deficiency Induces a Thyroid Stimulating Hormone-Independent Early Phase of Microvascular Reshaping in the Thyroid
Am. J. Pathol., March 1, 2008; 172(3): 748 - 760.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jlb.1105652v1
80/4/719    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pfaff, D.
Right arrow Articles by Augustin, H. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pfaff, D.
Right arrow Articles by Augustin, H. G.

HOME HELP FEEDBACK SUBSCRIPTIONS